logo-loader
viewCVS Health Corp

CVS Health to discontinue sales of popular Zantac heartburn treatment and its own generic products with the same active ingredient

The move comes after the US FDA said earlier this month that some of the pills contained small amounts of a known carcinogen

Pills
GlaxoSmithKline - the original makers of Zantac - is also reported to have stopped distributing its generic version of the drug

CVS Health Corp. (NYSE:CVS) is to discontinue sales of the Zantac heartburn treatment and its own generic products with the same active ingredient, ranitidine in them from its pharmacies, the US retailer said at the weekend.

The move comes after the US Food and Drug Administration (FDA) said earlier this month that some of the pills contained small amounts N-nitrosodimethylamine (NDMA),  a known carcinogen, which has also been found in some widely used blood pressure medicines.

In a statement, CVS said the move to suspend over-the-counter sales of the popular heartburn drug was taken out of caution while the FDA continues to review if low levels of NDMA in ranitidine poses a health risk to patients.

The retailer noted that Zantac brand products and CVS brand ranitidine products have not been recalled, and the FDA is not currently recommending that patients stop taking ranitidine.

Last week Sandoz, a unit of Swiss drugs giant Novartis said it was halting distribution of Zantac in all its markets, including the United States and Canada, following safety review of the drug by US and European drug regulators.

GlaxoSmithKline PLC (LON:GSK) - the original makers of Zantac - is also reported to have stopped distributing its generic version of the drug and recalled its products from India and Hong Kong, according to a report on the BBC’s website.

Contact the author at [email protected]

Quick facts: CVS Health Corp

Price: 64.7 USD

NYSE:CVS
Market: NYSE
Market Cap: $84.57 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Electric vehicle sales to accelerate following coronavirus pandemic

Roskill analyst Jose Lazuen tells Proactive London's Andrew Scott severe falls were expected in EV sales but that European and Chinese policies coupled with consumer preferences have shown them to remain strong. He adds that policy is going to favour and push EV sales in certain jurisdictions...

2 days, 9 hours ago

2 min read